Peptide Library

FDA-approved

Heart & blood

Motixafortide

Evidence

FDA approved

Class

CXCR4 antagonist peptide

/

Motixafortide

KEY TAKEAWAY

Motixafortide is a synthetic cyclic peptide that blocks the CXCR4 receptor. It is sold as Aphexda. The FDA approved motixafortide (Aphexda) in September 2023, used with filgrastim, to mobilize stem cells in multiple myeloma.

Written by the Veylo editorial team · Updated

November 2026

At a glance

At a glance

What it is

CXCR4 antagonist peptide

Approved for

Mobilizing stem cells for transplant in multiple myeloma

Key fact

The FDA approved motixafortide (Aphexda) in September 2023, used with filgrastim, to mobilize stem cells in multiple myeloma.

Route

Subcutaneous injection

Evidence strength

FDA approved

What it is

What it is

Motixafortide is a synthetic cyclic peptide that blocks the CXCR4 receptor. It is sold as Aphexda.

How it works

How it works

It releases stem cells from the bone marrow into the blood, where they can be collected for a transplant.

Regulatory status

Regulatory status

The FDA approved motixafortide (Aphexda) in September 2023, used with filgrastim, to mobilize stem cells in multiple myeloma.

What it is used for

What it is used for

Mobilizing stem cells for transplant in multiple myeloma.

Side effects and risks

Side effects and risks

Injection-site reactions, itching, flushing and back pain are common. Serious allergic reactions can occur.

Citations

Citations

U.S. FDA prescribing information for Motixafortide. DailyMed, National Library of Medicine.

Veylo content is educational and not medical advice. Peptides that are not FDA-approved are not approved for the uses described.

Veylo

Clinician-guided peptide care, paired with baseline blood testing and ongoing support.

Peptides referenced on this site are compounded medications and are investigational; they have not been approved by the FDA for the uses described. Nothing here is medical advice. Prescriptions are issued only after a licensed clinician reviews your history.

© 2026 Veylo. All rights reserved.

Veylo

Veylo

Veylo